| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1/2 data readout example | zoldonrasib (RMC-9805) metastatic RAS G12D pancreatic ductal adenocarcinoma (PDAC), first-line (zoldonrasib + chemotherapy) | Phase 1/2 | — | Small Molecules | Oncology | ||
Phase 1/2 data readout example | zoldonrasib (RMC-9805) metastatic RAS G12D pancreatic ductal adenocarcinoma (PDAC), first-line (zoldonrasib + chemotherapy) | Phase 1/2 | — | Small Molecules | Oncology | ||
Phase 1/2 data readout example | zoldonrasib (RMC-9805) metastatic RAS G12D pancreatic ductal adenocarcinoma (PDAC), first-line (zoldonrasib + chemotherapy) | Phase 1/2 | — | Small Molecules | Oncology |
Recent Updates
Recently added Catalysts
Revolution Medicines, Inc.$187.51
+0.23 (+0.12%)
C 56Pipeline Score Richly Valued Biotech · Commercial
Market Cap
32.22 B
EPS
-7.07
P/E Ratio
-
Value Trade
311.37 M
SEC Financials
Q1 2026Dilution Risk
25%R&D Expenses
343.97 M
Operating CF
-354.17 M
Total Assets
2.25 B
Total Liabilities
753.82 M
Equity
1.50 B
D/E Ratio
12,345
2.52 %
Week
1.26 %
1 Month
47.55 %
3 Month
116.3 %
6 Month
380.84 %
5 Year
437.26 %
All Time
Cash Data
Cash Position
1.91 B
Monthly Burn
118.06 M
Runway
14.5 mo
Burn Trend
SEC Filing
May 6, 2026
Overview
Volume
2.08 M
52 Week Range
34 - 156.25
% held by Insiders
10.58 %
% held by Institutions
86.07 %
Enterprise Value
30.75 B
Total Shares
212.60 M
Short %
6.46 %
Float Shares
192.82 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Revolution Medicines, Inc.
461Total events
10Upcoming
76Tier-1 (high impact)
2020 – 2026Coverage
Upcoming catalysts 10
Jul 2, 2026
T2Oral Presentation
Safety and Efficacy of Zoldonrasib Plus Daraxonrasib in 2L+ KRAS G12D mPDAC
Jul 3, 2026
T3Poster Presentation
RASolute 304: Phase 3 trial of adjuvant daraxonrasib vs observation in resected PDAC
2026-H1
T2Trial Initiation
Registrational trial for zoldonrasib combination expected to initiate in first half of 2026
2026-H1
T3Additional Data
Updated daraxonrasib monotherapy and daraxonrasib plus GnP combination data expected in first half of 2026
Event history 451
Jun 23, 2026
▲First Patient DosedZoldonrasibTrial
First patient dosed in RASolute 305 Phase 3 trial of zoldonrasib plus chemotherapy in first-line metastatic RAS G12D PDAC
metastatic RAS G12D pancreatic ductal adenocarcinomasource ↗
May 31, 2026
▲Oral PresentationDaraxonrasibPresentation
ASCO Plenary Session late-breaking presentation of RASolute 302 results
previously treated metastatic pancreatic ductal adenocarcinomasource ↗
May 31, 2026
▲Topline ReadoutDaraxonrasibClinical Data
Positive topline results from RASolute 302 trial
metastatic pancreatic ductal adenocarcinoma (PDAC)source ↗
May 31, 2026
▲PublicationDaraxonrasibPresentation
Results published in The New England Journal of Medicine
previously treated metastatic pancreatic ductal adenocarcinomasource ↗
May 6, 2026
▲PublicationDaraxonrasibPresentation
NEJM publication of Phase 1/2 data for daraxonrasib in PDAC
pancreatic ductal adenocarcinomasource ↗
Apr 21, 2026
◆Oral PresentationRM-055Presentation
Preclinical data on RM-055 at AACR 2026
KRAS G12 mutant cancerssource ↗
Apr 21, 2026
◆Oral PresentationDaraxonrasibPresentation
Daraxonrasib plus chemotherapy combination cohort data presented at AACR 2026
metastatic pancreatic ductal adenocarcinoma (PDAC)source ↗
Apr 21, 2026
◆Poster PresentationDaraxonrasibPresentation
Daraxonrasib monotherapy cohort data presented at AACR 2026
metastatic pancreatic ductal adenocarcinoma (PDAC)source ↗
Drug Pipeline Intelligence
C56
Pipeline Score $3.2B
Pipeline ValueRichly Valued
Valuation Signal9
Drugs Scored0.1x
rNPV / MCap Top 85%
Mid Cap (rank 137 of 905)
Percentile RankRevolution Medicines, Inc. carries a moderate pipeline score (56/100), with $3.7B risk-adjusted pipeline value, led by daraxonrasib in NSCLC (Non-small Cell Lung Cancer) (Phase 3), across $128B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| daraxonrasib Small molecule | Pancreatic Cancer | Phase 3 | NCT07252232 | 42% | $2.0B | RECRUITING | 1,400 | VERY_FAST | C (51) | Jul 10, 2030 | LOW_RISK | LOW Jun 22, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
elironrasib | KRAS G12C non-small cell lung cancer | 1 | 2025-10-22 | |||
elironrasib | KRAS G12C non-small cell lung cancer | 1 | 2025-10-22 | |||
elironrasib | KRAS G12C non-small cell lung cancer | 1 | 2025-10-22 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in RVMD
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
RVMD
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
RVMD
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
RVMD
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
RVMD Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
RVMD Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
RVMDRevolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
Revolution Medicines announced that it will present clinical data from its RAS(ON) inhibitor combination trials at the 2026 ESMO Gastrointestinal Cancers Congress. The presentations will include results from Phase 1/2 trials of zoldonrasib in combination with chemotherapy and daraxonrasib. Additionally, two Phase 3 trials-in-progress will be showcased, focusing on daraxonrasib as a treatment for metastatic pancreatic ductal adenocarcinoma.
Read more →RVMDRevolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic Cancer
Revolution Medicines has commenced patient treatment in the RASolute 305 trial, which evaluates zoldonrasib combined with chemotherapy for metastatic RAS G12D pancreatic cancer. This Phase 3 trial aims to determine if the combination can enhance overall survival and progression-free survival. The study follows previous positive results from daraxonrasib, indicating the potential of RAS(ON) inhibitors in treating pancreatic cancer.
Read more →RVMDRevolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D.
Revolution Medicines announced that Steve Kelsey, M.D., will transition to a senior advisor role ahead of his planned retirement in January 2027. The company is restructuring its R&D leadership to maintain momentum in its oncology programs. Kelsey has been pivotal in advancing the company's drug development efforts since 2017.
Read more →RVMDPlatform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
Biotechnology companies are increasingly focusing on enhancing existing therapies through advanced drug delivery technologies, particularly in oncology. Oncotelic Therapeutics is at the forefront with its Sapu003 program and Deciparticle platform, aiming to improve drug exposure and effectiveness. The global oncology drug market is expected to grow significantly, driven by rising cancer rates and advancements in treatment methods. However, challenges such as regulatory hurdles and high development costs remain prevalent.
Read more →RVMDRevolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
Revolution Medicines announced positive results from the Phase 3 RASolute 302 trial of daraxonrasib for previously treated metastatic pancreatic cancer. The trial showed unprecedented improvements in overall and progression-free survival compared to standard chemotherapy. Daraxonrasib also exhibited a manageable safety profile and improved quality of life for patients. The results will be presented at the ASCO Annual Meeting.
Read more →RVMDRevolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation
Revolution Medicines announced a webcast on May 31, 2026, to discuss positive results from the Phase 3 RASolute 302 trial of daraxonrasib for metastatic pancreatic ductal adenocarcinoma. This follows the presentation of the trial data at the 2026 ASCO Annual Meeting. The company is focused on developing targeted therapies for RAS-addicted cancers.
Read more →RVMDRevolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer
Revolution Medicines announced the publication of Phase 1/2 clinical trial data for daraxonrasib in the New England Journal of Medicine. The trial showed promising results in treating patients with metastatic RAS mutant pancreatic ductal adenocarcinoma (PDAC), leading to the initiation of a global Phase 3 trial, RASolute 302. The drug demonstrated significant antitumor activity and favorable safety profiles. Additionally, daraxonrasib is being tested in multiple ongoing Phase 3 trials for various cancers related to RAS mutations.
Read more →RVMDRevolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress
Revolution Medicines reported strong financial results for Q1 2026, highlighting the success of daraxonrasib in the Phase 3 RASolute 302 trial for metastatic pancreatic cancer. The company plans to submit these results to global regulatory authorities, including the FDA. Additionally, they raised $2.2 billion to support their RAS(ON) portfolio and continue advancing their clinical trials across various cancer types.
Read more →RVMDRevolution Medicines to Report Financial Results for First Quarter 2026 After Market Close on May 6, 2026
Revolution Medicines, Inc. will report its financial results for Q1 2026 on May 6, 2026, after market close. A webcast will follow at 4:30 p.m. ET, where senior management will discuss the results and provide updates on the company's progress in developing targeted therapies for RAS-addicted cancers. Archived access will be available for 14 days.
Read more →RVMDRevolution Medicines to Present Preclinical Data on Innovative Mutant-Targeted Catalytic RAS(ON) Inhibitor at the 2026 AACR Annual Meeting
Revolution Medicines, Inc. has announced promising preclinical data on a new class of mutant-targeted catalytic RAS(ON) inhibitors aimed at addressing RAS-addicted cancers. The lead candidate, RM-055, showcases significant tumor regression and the ability to overcome resistance to existing RAS inhibitors in multiple cancer types. This innovative approach could offer a therapeutic advantage by maintaining effectiveness in tumors with heightened RAS signaling. The data will be presented at the AACR Annual Meeting on April 21, 2026.
Read more →RVMDRevolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual Meeting
Revolution Medicines, Inc. announced that results from the pivotal Phase 3 RASolute 302 clinical trial of daraxonrasib will be presented at the 2026 ASCO Annual Meeting. The trial evaluated the efficacy of daraxonrasib in patients with previously treated metastatic pancreatic ductal adenocarcinoma, showing significant overall survival benefits compared to standard chemotherapy. The presentation is expected to elaborate on key findings related to progression-free survival and the drug's safety profile.
Read more →RVMDRevolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting
Revolution Medicines announced updated clinical data for daraxonrasib in Phase 1/2 trials targeting metastatic pancreatic cancer. The findings indicate manageable safety profiles and early signs of durable antitumor activity for both monotherapy and combination therapy. The data will be presented at the AACR Annual Meeting, supporting further evaluation in ongoing trials.
Read more →RVMDRevolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual Meeting
Revolution Medicines announced updated Phase 1 clinical data for zoldonrasib, a selective inhibitor for KRAS G12D non-small cell lung cancer (NSCLC), at the AACR Annual Meeting. The trial demonstrated a manageable safety profile and promising efficacy, with a 52% objective response rate among previously treated patients. The data supports further development of zoldonrasib as a targeted therapy for this patient population.
Read more →RVMDRevolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Revolution Medicines, Inc. has successfully closed upsized public offerings totaling approximately $2.2 billion, which includes both a common stock offering and convertible senior notes. The funds are earmarked for general corporate purposes, primarily focusing on research and development as well as potential commercialization of its therapies for RAS-addicted cancers. The company’s offerings took place under an effective shelf registration statement filed with the SEC. This financial maneuver highlights the confidence market players have in Revolution Medicines' future endeavors.
Read more →RVMDRevolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes
Revolution Medicines has announced the pricing of its concurrent public offerings totaling $2.0 billion, consisting of $1.5 billion in common stock and $500 million in convertible senior notes. The offerings were upsized due to strong demand and are set to settle in mid-April 2026. Proceeds will be used for corporate purposes, including R&D for cancer therapies.
Read more →RVMDRevolution Medicines, Inc. Announces Proposed Offerings of Common Stock and Convertible Senior Notes
Revolution Medicines announced plans to offer $750 million in common stock and $250 million in convertible senior notes. The offerings will support their R&D efforts for targeted therapies in oncology. The completion of each offering is independent, and underwriters have options for additional purchases. Proceeds will be used for general corporate purposes.
Read more →RVMDRevolution Medicines Begins Treating Patients in Phase 3 RASolute 303 Trial Evaluating Daraxonrasib as First Line Treatment for Patients with Metastatic Pancreatic Cancer
Revolution Medicines has commenced patient treatment in its Phase 3 RASolute 303 clinical trial of daraxonrasib, aimed at patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC). The trial seeks to evaluate daraxonrasib both as a standalone therapy and in combination with standard chemotherapy. This initiative highlights the company's commitment to addressing the significant unmet medical needs of pancreatic cancer patients. Primary endpoints include progression-free survival and overall survival, with the trial designed to accommodate patients regardless of their RAS genotype.
Read more →RVMDRevolution Medicines to Showcase Progress Across RAS(ON) Targeted Oncology Pipeline with Multiple Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting
Revolution Medicines will present nine oral and poster presentations at the 2026 AACR Annual Meeting, highlighting advancements in its RAS(ON) inhibitor pipeline. Key presentations include Phase 1 data for zoldonrasib in KRAS G12D mutant non-small cell lung cancer and Phase 1/2 data for daraxonrasib in metastatic pancreatic ductal adenocarcinoma. The presentations reflect the company's commitment to addressing resistance in RAS-driven cancers.
Read more →RVMDRevolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress
Revolution Medicines reported its financial results for Q4 and full year 2025, highlighting substantial progress in its RAS(ON) inhibitors for RAS-addicted cancers. The company anticipates pivotal data from its daraxonrasib study in pancreatic cancer in 2026. Despite a significant net loss, its cash reserves remain strong at $2.0 billion, supporting ongoing clinical trials.
Read more →RVMDRevolution Medicines to Participate in TD Cowen 46th Annual Health Care Conference
Revolution Medicines, Inc. will participate in the TD Cowen 46th Annual Health Care Conference on March 3, 2026. CEO Mark A. Goldsmith will lead a fireside chat at 9:50 a.m. ET, discussing the company's targeted therapies for RAS-addicted cancers. A live webcast and archived replay will be available on the company's website.
Read more →RVMDRevolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026
Revolution Medicines, Inc. has announced that it will report its financial results for the fourth quarter and full year of 2025 on February 25, 2026, after market close. The announcement highlights that a webcast hosted by the senior management team will take place at 4:30 p.m. ET to discuss the results and provide updates on corporate progress. Interested parties can access the live event and a replay afterward on the company's website.
Read more →RVMDRevolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Revolution Medicines, Inc. will participate in the Guggenheim Securities Emerging Outlook: Biotech Summit 2026. CEO Mark A. Goldsmith will engage in a fireside chat on February 11 at 9:30 a.m. ET. The event will be available via live webcast and archived for later access. The company specializes in targeted therapies for RAS-addicted cancers.
Read more →RVMDRevolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor
Revolution Medicines has initiated its first-in-human clinical trial for RMC-5127, a targeted therapy designed to inhibit the RAS G12V mutation associated with various cancers. This trial aims to assess the safety and preliminary antitumor activity of the drug, enrolling patients with RAS G12V-mutated solid tumors who have not responded to existing therapies. The development of RMC-5127 is notable as it addresses a critical unmet need in cancer treatment, particularly for the second most common RAS mutation. The company's approach highlights a broader portfolio aimed at improving patient outcomes in RAS-driven cancers.
Read more →RVMDRevolution Medicines Announces FDA Breakthrough Therapy Designation for Zoldonrasib
Revolution Medicines has received Breakthrough Therapy Designation from the FDA for zoldonrasib, aimed at treating adult patients with KRAS G12D-mutated non-small cell lung cancer (NSCLC) who have previously been treated with anti-PD-1/PD-L1 therapy and platinum-based chemotherapy. This marks the first-ever designation for an investigational drug specifically targeting the KRAS G12D mutation. Data from the Phase 1 clinical trial indicates promising antitumor activity and acceptable safety. Zoldonrasib is part of a series of RAS(ON) inhibitors under development by Revolution Medicines, addressing a significant treatment gap in this patient population.
Read more →RVMDRevolution Medicines to Present at 44th Annual J.P. Morgan Healthcare Conference
Revolution Medicines, Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. CEO Mark A. Goldsmith is set to deliver the corporate presentation, which will be accessible via a live webcast. The company focuses on developing targeted therapies for RAS-addicted cancers, with several candidates in clinical development.
Read more →RVMDRevolution Medicines Announces First Patient Randomized in the RASolute 304 Clinical Trial of Daraxonrasib in Resectable Pancreatic Ductal Adenocarcinoma Following Adjuvant Chemotherapy
Revolution Medicines has announced the randomization of its first patient in the RASolute 304 clinical trial, which assesses the safety and efficacy of daraxonrasib in patients with resectable pancreatic ductal adenocarcinoma post-chemotherapy. The trial aims to enroll around 500 participants to evaluate if daraxonrasib can improve disease-free survival compared to observation. This initiative represents an important step for early intervention in the treatment of pancreatic cancer, a historically difficult-to-treat disease.
Read more →RVMDRevolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress
Revolution Medicines reported its Q3 2025 financial results, highlighting progress in its RAS(ON) inhibitor programs. The company is nearing completion of enrollment for pivotal trials of daraxonrasib in pancreatic and lung cancers, with promising data supporting its ongoing development. Despite a significant net loss, the company maintains a strong cash position and is advancing multiple clinical trials.
Read more →RVMDRevolution Medicines to Participate in November 2025 Investor Conferences
Revolution Medicines, Inc. has announced that CEO Mark A. Goldsmith will participate in two upcoming investor conferences. The company specializes in developing targeted therapies for RAS-addicted cancers and has a robust pipeline of RAS(ON) inhibitors currently in clinical development. Archived webcasts of the events will be available on their website.
Read more →RVMDRevolution Medicines to Report Financial Results for Third Quarter 2025 After Market Close on November 5, 2025
Revolution Medicines, Inc. will report its financial results for Q3 2025 on November 5, 2025, after market close. A webcast will be hosted by the senior management team at 4:30 p.m. ET to discuss these results and provide updates on corporate progress. The company focuses on developing targeted therapies for RAS-addicted cancers.
Read more →RVMDRevolution Medicines’ RAS(ON) Multi-Selective Inhibitor Daraxonrasib Granted U.S. FDA Orphan Drug Designation in Pancreatic Cancer
Revolution Medicines has announced that the FDA granted Orphan Drug Designation to daraxonrasib for treating pancreatic cancer. This designation highlights the urgent need for innovative therapies targeting RAS mutations, which are prevalent in pancreatic cancer cases. The company is also advancing multiple Phase 3 clinical trials for daraxonrasib in various treatment settings.
Read more →RVMDRevolution Medicines to Present Updated Elironrasib Safety and Efficacy Data in Patients with KRAS G12C Non-Small Cell Lung Cancer Following Treatment with a KRAS(OFF) G12C Inhibitor
Revolution Medicines announced updated clinical data for elironrasib, a selective inhibitor for KRAS G12C non-small cell lung cancer, showing promising efficacy in patients previously treated with KRAS(OFF) inhibitors. The data, to be presented at the AACR-NCI-EORTC Symposium, highlights a 42% objective response rate and a 62% 12-month overall survival rate. Elironrasib's potential as a new standard of care is emphasized by the company's leadership.
Read more →RVMDRevolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under FDA Commissioner's National Priority Voucher Pilot Program
Revolution Medicines has been awarded a non-transferrable voucher for daraxonrasib (RMC-6236) by the FDA under the Commissioner's National Priority Voucher pilot program. This recognition highlights the drug's potential in treating RAS-addicted cancers, particularly in ongoing Phase 3 trials for pancreatic and lung cancer. The company remains focused on its development timelines despite receiving the voucher.
Read more →RVMDRevolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer
Revolution Medicines has appointed Alan Sandler, M.D. as Chief Development Officer to enhance its leadership team. This move comes as the company prepares for potential approvals and commercial launches of its RAS(ON) inhibitors. Additionally, regional general managers for the U.S. and Europe have been appointed to strengthen global commercial capabilities.
Read more →RVMDRevolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma
Revolution Medicines has announced positive long-term follow-up data for daraxonrasib in treating metastatic pancreatic ductal adenocarcinoma (PDAC). The results support the initiation of the RASolute 303 Phase 3 trial, which will evaluate daraxonrasib both as a monotherapy and in combination with chemotherapy. The trial is set to begin in Q4 2025, reflecting the company's commitment to improving treatment options for patients.
Read more →RVMDRevolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress
Revolution Medicines reported its Q2 2025 financial results, highlighting progress in pivotal trials for daraxonrasib in treating RAS-addicted cancers. The company received Breakthrough Therapy Designation for both daraxonrasib and elironrasib, while also announcing a partnership with Royalty Pharma for funding. Despite a net loss increase, the company maintains a strong cash position.
Read more →RVMDRevolution Medicines to Report Financial Results for Second Quarter 2025 After Market Close on August 6, 2025
Revolution Medicines, Inc. will report its financial results for Q2 2025 on August 6, 2025, after market close. A webcast will follow at 4:30 p.m. ET, where senior management will discuss the results and corporate updates. The company is focused on developing targeted therapies for RAS-addicted cancers.
Read more →RVMDRevolution Medicines Announces Publication of a Peer-Reviewed Research Paper in Science on the Discovery and Development of Zoldonrasib, a RAS(ON) G12D-Selective Inhibitor
Revolution Medicines has announced the publication of a peer-reviewed paper in Science detailing the discovery and development of zoldonrasib, a selective covalent inhibitor targeting the RAS G12D mutation. Zoldonrasib has shown substantial efficacy, inducing deep tumor regressions in preclinical models. The publication emphasizes its unique mechanism, which effectively engages aspartic acid residues, overcoming traditional targeting challenges associated with RAS mutations. The compound is under evaluation in multiple clinical trials for advanced tumors harboring the KRAS G12D mutation.
Read more →RVMDRevolution Medicines Announces FDA Breakthrough Therapy Designation for Elironrasib
Revolution Medicines has announced that the FDA granted Breakthrough Therapy Designation for elironrasib, a treatment for adult patients with KRAS G12C-mutated non-small cell lung cancer. This designation is based on encouraging data from a Phase 1 clinical trial demonstrating strong antitumor activity. Elironrasib targets patients who have previously received chemotherapy and immunotherapy but not a KRAS G12C inhibitor. This designation underscores the need for more targeted therapies for RAS-addicted cancers.
Read more →RVMDRevolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic’s AI Discovery Tools to Pursue New Drug Candidates
Revolution Medicines has entered into a multi-year collaboration with Iambic Therapeutics to advance drug discovery using Iambic's AI-driven models. The agreement includes the training of custom versions of Iambic's NeuralPLexer model with Revolution's proprietary data, with up to $25 million in funding involved. Both companies will work together to uncover new drug candidates targeting challenging oncology areas, leveraging advanced AI capabilities for better outcomes. This partnership aims to enhance the drug discovery process significantly.
Read more →RVMDRevolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors
Revolution Medicines and Summit Therapeutics have initiated a clinical collaboration to assess the safety and efficacy of three RAS(ON) inhibitors combined with Summit's ivonescimab in treating RAS mutant tumors. This collaboration focuses on key cancer types, including non-small cell lung cancer, pancreatic ductal adenocarcinoma, and colorectal cancer. Both companies retain commercial rights to their respective therapies, with Summit providing ivonescimab for the trials. The agreement underscores the potential for these therapies to improve patient outcomes in challenging cancer types.
Read more →RVMDRevolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for Patients with RAS-Addicted Cancers Flexibl
Revolution Medicines, Inc. has entered into a significant funding agreement with Royalty Pharma, valued at up to $2 billion, aimed at supporting its RAS(ON) inhibitor portfolio. This partnership will enable Revolution Medicines to maintain full control over the clinical development and commercialization of its products. The agreement includes $1.25 billion in synthetic royalty monetization and $750 million in corporate debt, providing substantial capital while allowing flexibility in operational scaling. This innovative funding structure marks a shift in how biotech companies can secure financial resources for development.
Read more →RVMDRevolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS G12 Mutations
Revolution Medicines has announced that the FDA has granted Breakthrough Therapy Designation to daraxonrasib, a targeted therapy for previously treated metastatic pancreatic cancer with KRAS G12 mutations. This designation is based on promising early clinical data from the Phase 1 study, which highlighted the drug's potential to significantly improve patient outcomes. The company is currently enrolling patients in a Phase 3 study, RASolute 302, which is set to substantially complete enrollment this year, with expected results in 2026. The initiative underscores a critical need for effective therapies in a disease with high mortality rates and limited treatment options.
Read more →RVMDRevolution Medicines Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating Daraxonrasib in Previously Treated Patients with RAS Mutant Non-Small Cell Lung Cancer
Revolution Medicines has commenced dosing in its Phase 3 clinical trial, RASolve 301, evaluating the efficacy of daraxonrasib in previously treated patients with RAS mutant non-small cell lung cancer (NSCLC). This pivotal trial aims to enroll approximately 420 patients globally and focuses on assessing daraxonrasib's safety and efficacy compared to traditional chemotherapy. Given the lack of approved targeted therapies for many RAS mutations, the trial seeks to explore daraxonrasib as a promising treatment avenue for a significant subset of NSCLC patients. The trial is informed by initial evidence suggesting acceptable safety and encouraging antitumor activity.
Read more →RVMDRevolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress • Strong execution of two ongoing Phase 3 trials of daraxonrasib; company expects to substantially complete enroll
Revolution Medicines reported its financial results for Q1 2025 and provided an update on its corporate progress, highlighting strong advancements in ongoing Phase 3 trials of daraxonrasib. The company expects substantial enrollment completion in the RASolute 302 trial for pancreatic cancer this year. Additionally, encouraging data was shared regarding the efficacy of zoldonrasib and elironrasib in previously treated NSCLC patients. The appointment of Anthony Mancini as chief global commercialization officer signifies a commitment to strengthening commercial operations and capabilities.
Read more →RVMDRevolution Medicines to Report Financial Results for First Quarter 2025 After Market Close on May 7, 2025
Revolution Medicines, Inc. will report its financial results for the first quarter of 2025 on May 7, 2025, after market close. A webcast is scheduled for 4:30 p.m. ET on the same day, where senior management will discuss the results and corporate advancements. The webcast will be accessible live and archived on the company's website for at least 14 days thereafter. This event reflects the company's ongoing efforts in the oncology sector, focusing on RAS-addicted cancers.
Read more →RVMDRevolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting
Revolution Medicines announced promising data on zoldonrasib (RMC-9805), a selective inhibitor for KRAS G12D mutant non-small cell lung cancer, at the AACR Annual Meeting. In a Phase 1 study, the drug showed an encouraging objective response rate of 61% and well-tolerated safety profile among patients. The data suggests potential for zoldonrasib as a treatment option for this patient population, where current targeted therapies are lacking. Further evaluation in larger patient groups is planned to confirm these initial findings.
Read more →RVMDRevolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting
Revolution Medicines, Inc. has announced that it will deliver 11 oral and poster presentations at the upcoming AACR Annual Meeting in Chicago from April 25 to 30, 2025. A highlight will be the first clinical data from its Phase 1 study of zoldonrasib, a selective inhibitor targeting RAS(ON) G12D, specifically in non-small cell lung cancer. The presentations will cover various aspects of oncology, including breakthrough findings and potential therapeutic strategies for RAS-addicted cancers.
Read more →RVMDRevolution Medicines to Participate in April 2025 Investor Conferences
Revolution Medicines, Inc. will participate in two upcoming investor conferences in April 2025. The CEO, Dr. Mark A. Goldsmith, is set to take part in the Needham 24th Annual Virtual Healthcare Conference and the Stifel 2025 Virtual Targeted Oncology Forum. These events could provide opportunities for the company to engage with investors and promote its oncology therapies aimed at RAS-addicted cancers.
Read more →RVMDRevolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress Company anticipates substantially completing enrollment this year in ongoing Phase 3 RASolute 302 trial of
Revolution Medicines reported its financial results for Q4 2024 and full year, highlighting advances in clinical trials for daraxonrasib in RAS-addicted cancers. The company expects to complete enrollment in the Phase 3 RASolute 302 trial for pancreatic cancer this year, with data readout anticipated in 2026. Additional trials for non-small cell lung cancer and other combinations are also in progress, reinforcing its commitment to innovative cancer treatments.
Read more →RVMDRevolution Medicines to Participate in March 2025 Investor Conferences
Revolution Medicines, Inc. will participate in several investor conferences in March 2025, showcasing its commitment to engaging with the investment community. CEO Mark A. Goldsmith will be featured in fireside chats at three notable conferences. These events will allow the company to present its progress in developing targeted therapies for RAS-addicted cancers, reflecting its active role in oncology. Archived webcasts will be available on the company's website following each event.
Read more →RVMDRevolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025
Revolution Medicines, Inc. announced its plans to report financial results for the fourth quarter and full year of 2024 on February 26, 2025, after market close. The report will be followed by a webcast discussion with the company's senior management team, aimed at providing insights into the results and an update on corporate progress. Investors can access the live webcast and its replay on the company's website for two weeks after the event.
Read more →RVMDRevolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference
Revolution Medicines, Inc. announced that its CEO Mark A. Goldsmith will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on February 5, 2025. The conference aims to showcase insights into their development of targeted therapies for RAS-addicted cancers. A live webcast of the event will be available along with a replay for 14 days post-conference.
Read more →RVMDRevolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference
Revolution Medicines, Inc. has announced that its CEO, Mark A. Goldsmith, will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025. The session will focus on the company's novel targeted therapies designed for RAS-addicted cancers. Additionally, information about accessing the live webcast and subsequent replay was provided. Revolution Medicines continues to develop a robust pipeline of RAS(ON) inhibitors aimed at treating various cancer indications.
Read more →RVMDRevolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares
Revolution Medicines, Inc. has announced the successful closing of a public offering, which raised approximately $862.5 million through the sale of 16,576,088 shares of common stock priced at $46.00 each. The offering also included pre-funded warrants to purchase an additional 2,173,917 shares. The proceeds will support the company's ongoing development of RAS(ON) inhibitors targeting RAS-addicted cancers. This financial boost is significant for their pipeline advancements.
Read more →RVMDRevolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants
Revolution Medicines has announced the pricing of a $750 million public offering of common stock and pre-funded warrants. The offering includes over 14 million shares priced at $46 each and a substantial number of warrants. This capital raise is aimed at supporting the company's ongoing development of targeted therapies for patients with RAS-addicted cancers. The offering is scheduled to close on December 5, 2024, pending customary closing conditions.
Read more →RVMDRevolution Medicines Announces Commencement of Public Offering of Common Stock
Revolution Medicines, Inc. has announced the commencement of a public offering of common stock valued at up to $600 million. The offering comes with a 30-day option for underwriters to purchase an additional $90 million worth of shares. The actual completion of the offering is uncertain and contingent upon market conditions. J.P. Morgan, TD Cowen, Goldman Sachs & Co. LLC, and Guggenheim Securities are managing the offering.
Read more →RVMDRevolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio
Revolution Medicines has released significant updates on its RAS(ON) inhibitor portfolio, specifically highlighting the Phase 1/1b studies for RMC-6236 in pancreatic ductal adenocarcinoma and non-small cell lung cancer. Initial results have shown compelling antitumor activity and a favorable safety profile for RMC-6236, with ongoing Phase 3 trials set to further assess its efficacy. The company has also indicated plans to evaluate the combination of RMC-6236 with pembrolizumab and the RAS(ON) inhibitor doublet consisting of RMC-6291 and RMC-6236. Overall, the updates affirm the company's commitment to innovating treatment options for patients with RAS-addicted cancers.
Read more →RVMDRevolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024
Revolution Medicines, Inc. has announced an investor webcast set for December 2, 2024, aimed at providing clinical updates on its RAS(ON) inhibitor portfolio. This webcast will focus on the company's ongoing clinical development of multiple RAS(ON) inhibitors, including RMC-6236, RMC-6291, and RMC-9805. The event reflects the company's commitment to targeted therapies for patients suffering from RAS-addicted cancers. An archived replay will be available on their website post-event.
Read more →RVMDRevolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress Phase 3 pivotal trial underway evaluating RMC-6236 in patients with metastatic pancreatic ductal adenocarcinoma (PDAC), s
Revolution Medicines has reported its financial results for Q3 2024 and provided an update on its drug trials. The Phase 3 trial for RMC-6236 in metastatic pancreatic ductal adenocarcinoma (PDAC) is ongoing, showing promising clinical profiles. Initial results for RMC-9805 indicate encouraging safety and efficacy against KRAS G12D mutations. Despite a significant net loss for the quarter, the company remains optimistic about upcoming updates on its cancer treatments.
Read more →RVMDRevolution Medicines to Participate in Upcoming Investor Conferences
Revolution Medicines, Inc. will participate in two upcoming investor conferences, where CEO Mark A. Goldsmith will speak. The Guggenheim Healthcare Innovation Conference is scheduled for November 11-13, 2024, and the UBS Global Healthcare Conference will take place from November 11-14, 2024. Both events will offer webcasts for attendees, allowing broader access to the discussions on the company's targeted therapies for RAS-addicted cancers. This participation highlights the company's ongoing developments in oncology.
Read more →RVMDRevolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024
Revolution Medicines, Inc. will report its financial results for the third quarter of 2024 on November 6, 2024, after the market closes. The senior management team will hold a webcast at 4:30 p.m. Eastern Time to discuss the results and provide an update on the company's corporate progress. Revolution Medicines is focused on developing targeted therapies specifically for RAS-addicted cancers, with multiple inhibitors in clinical development.
Read more →RVMDRevolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma
Revolution Medicines has announced initial findings from its clinical trial of RMC-9805, a RAS(ON) G12D-selective inhibitor for patients with advanced pancreatic ductal adenocarcinoma (PDAC). The data, presented at a prominent medical symposium, indicates that RMC-9805 has a favorable safety profile and shows encouraging antitumor activity, with a 30% objective response rate observed in treated patients. While the results are promising, they are preliminary and derived from a limited patient cohort, raising caution in their interpretation.
Read more →RVMDRevolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma
Revolution Medicines has announced positive updates regarding RMC-6236, a multi-selective inhibitor for pancreatic ductal adenocarcinoma (PDAC). The data presented during the EORTC-NCI-AACR Symposium indicate promising progression-free and overall survival rates in treated patients, reinforcing the drug’s potential as a therapeutic option. Safety profiles remain consistent with previous reports, showing no new safety concerns. This sets the stage for ongoing Phase 3 studies as researchers continue to explore the treatment's efficacy in RAS-mutated cancers.
Read more →RVMDRevolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Revolution Medicines has announced the dosing of the first patient in its Phase 3 RASolute 302 study for RMC-6236, aimed at treating previously treated patients with metastatic pancreatic ductal adenocarcinoma (PDAC). The study will assess the efficacy of RMC-6236 compared to standard chemotherapy in approximately 460 global participants. This milestone highlights the company's focus on targeting RAS mutations, which are prevalent in this aggressive cancer type. Initial data from prior trials indicates potential benefits of RMC-6236, although definitive results are pending.
Read more →RVMDRevolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast
Revolution Medicines, Inc. will present seven oral and poster presentations at the 2024 AACR-NCI-EORTC Symposium in Barcelona, scheduled for October 23-25, 2024. Notably, two late-breaking presentations will feature updated clinical data on their RMC-6236 and RMC-9805 monotherapy studies for pancreatic ductal adenocarcinoma (PDAC). Additionally, the company will host an investor webcast to discuss the findings on October 25, 2024, following the symposium's late-breaking session. Revolution Medicines continues to advance its RAS(ON) inhibitor clinical programs and intends to provide further updates in the coming quarter.
Read more →RVMDRevolution Medicines Reports Second Quarter 2024 Financial Results and Update on Corporate Progress Revolution Medicines to hold webcast today at 4:30 p.m. Eastern Time
Revolution Medicines reported its financial results for Q2 2024, highlighting progress in developing its drug RMC-6236 for RAS-addicted cancers, particularly pancreatic cancer and lung cancer. The company plans to initiate pivotal Phase 3 trials for RMC-6236 following promising preliminary data. Additionally, they are expanding treatment evaluation into earlier lines. The appointment of Frank Clyburn to the board is expected to enhance their leadership in advancing their clinical and commercial objectives.
Read more →RVMDRevolution Medicines to Report Financial Results for Second Quarter 2024 After Market Close on August 7, 2024
Revolution Medicines, Inc. is set to report its financial results for the second quarter of 2024 on August 7, 2024, following market close. The company's senior management will host a webcast at 4:30 p.m. Eastern Time to discuss these results and provide updates on corporate progress. Revolution Medicines specializes in developing targeted therapies for RAS-addicted cancers and has several RAS(ON) inhibitors in clinical development.
Read more →RVMDRevolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer
Revolution Medicines has announced a publication in Cancer Discovery showcasing the strong anti-tumor activity of its RAS(ON) multi-selective inhibitor RMC-7977. The research indicates that this inhibitor, when used alone or in combination with the RAS(ON) G12C-selective inhibitor RMC-4998, achieved durable tumor regressions in preclinical models of KRAS-mutated non-small cell lung cancer (NSCLC). These findings are noteworthy as they highlight a potential solution to the limitations of existing KRAS-targeted therapies, particularly against challenging mutations. The company is actively advancing clinical trials for its drug candidates based on the promising results of this research.
Read more →RVMDRevolution Medicines to Provide Update on RMC-6236 Pancreatic Ductal Adenocarcinoma Clinical Program on July 15, 2024
Revolution Medicines, Inc. has announced an upcoming investor webcast set for July 15, 2024, to update stakeholders on the clinical program for RMC-6236, a treatment for pancreatic ductal adenocarcinoma (PDAC). The event will feature members of the company's management and a noted expert from Harvard Medical School. Participants will be able to access the live webcast and a subsequent replay through the company's website. This initiative reflects the company’s commitment to transparency and advancement in RAS-addicted cancer therapies.
Read more →RVMDRevolution Medicines to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
Revolution Medicines, Inc. will participate in the upcoming Goldman Sachs 45th Annual Global Healthcare Conference. CEO Mark A. Goldsmith is scheduled to speak in a fireside chat on June 12, 2024. The conference will take place in Miami, Florida, from June 10 to 13, 2024. Investors can access the event via a live webcast on the company's website, with a replay available afterward. This participation may boost the company's profile in the competitive oncology sector.
Read more →RVMDRevolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress Revolution Medicines to hold webcast today at 4:30 p.m. Eastern Time
Revolution Medicines reported its financial results for Q1 2024, highlighting the advancement of RMC-6236 into pivotal trials for RAS-addicted cancers. Despite a net loss of $116 million and zero revenue due to the termination of a collaboration agreement, the company is progressing in clinical development with promising data on RMC-6236's efficacy. The firm maintains a solid cash position of $1.70 billion, allowing for continued investment in clinical trials. Additional RAS inhibitors are also under evaluation, expanding potential treatment options.
Read more →RVMDRevolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024
Revolution Medicines, Inc. has announced that it will report its financial results for the first quarter of 2024 after market close on May 8, 2024. A webcast hosted by senior management will provide insights into the financial results and updates on corporate progress. The company's focus remains on developing targeted therapies for RAS-addicted cancers, with several investigational drugs currently in clinical development.
Read more →RVMDRevolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
Revolution Medicines announced the publication of a peer-reviewed study on RMC-6236, a multi-selective inhibitor designed to target oncogenic RAS proteins in various cancers. The research shows that RMC-6236 effectively inhibits RAS-dependent tumor growth and is well-tolerated, resulting in significant tumor regressions. Early clinical data from the Phase 1/1b trial indicate complete responses in patients with advanced KRAS mutations. As the company plans further development, RMC-6236 is positioned to advance into pivotal studies.
Read more →RVMDRevolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
Revolution Medicines announced the publication of two papers in Nature detailing RMC-7977, a RAS(ON) multi-selective inhibitor. The research highlights RMC-7977's ability to effectively target both mutant and wild-type RAS proteins in preclinical studies, showcasing its significant anti-tumor activity across various cancer models. This innovative treatment strategy may overcome limitations faced by existing KRAS-targeted therapies. Additionally, ongoing trials for RMC-6236, a related investigational drug, aim to further evaluate its clinical efficacy in RAS-addicted cancers, marking an important advancement in oncology.
Read more →RVMDRevolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024
Revolution Medicines, Inc. announced its participation at the AACR Annual Meeting 2024, from April 5-10, 2024, in San Diego, California. The company will deliver multiple oral and poster presentations highlighting its targeted therapies for RAS-addicted cancers. Key topics include innovative RAS(ON) inhibitors and their efficacy against various cancer types. This event is pivotal for showcasing the company's advancements in oncology research and therapy development.
Read more →RVMDRevolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress Revolution Medicines to hold webcast today at 4:30 p.m. Eastern Time
Revolution Medicines has reported its financial results for Q4 and FY 2023, highlighting a robust cash position of $1.85 billion following the acquisition of EQRx. The company is advancing its RAS(ON) inhibitors, with pivotal trials for RMC-6236 planned for the second half of 2024. However, revenue dropped sharply due to the end of a collaboration agreement with Sanofi, indicating potential financial challenges moving forward. Overall, the company maintains an optimistic outlook with ongoing clinical trials showing positive antitumor activity.
Read more →RVMDRevolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024
Revolution Medicines, Inc. has announced that it will report its financial results for the fourth quarter and full year of 2023 on February 26, 2024. The company will hold a webcast at 4:30 p.m. Eastern Time to discuss these results and provide an update on its corporate activities. Revolution Medicines is focused on developing targeted therapies for RAS-addicted cancers, with several inhibitors currently in clinical development. The webcast will also be available for replay on the company's website for at least 14 days.
Read more →RVMDRevolutionising Facial Rejuvenation: McKeown Medical Release Comprehensive Guide to Cutting-Edge Facelift Techniques
McKeown Medical, led by Dr. Darren McKeown, has launched a Comprehensive Guide detailing innovative facelift techniques. This guide aims to inform prospective patients about the variety of procedures available, including both surgical and non-surgical options designed to meet personal aesthetic goals. With a focus on tailored treatments, the clinic seeks to enhance patient confidence and achieve natural-looking results. The Comprehensive Guide comes in response to the growing popularity of facelift procedures, particularly among individuals in their late 40s to 60s.
Read more →RVMDOn Target to Outsmart Cancer
Revolution Medicines, Inc. is focusing on treating RAS-addicted cancers through its RAS(ON) inhibitors, notably RMC-6236 and RMC-6291, which are demonstrating promising initial clinical profiles. The company is advancing these drug candidates towards late-stage development while addressing the potential market for RAS-mutant cancers. However, the candidates are still under clinical investigation and not yet approved by the FDA, which poses inherent risks and uncertainties. Treatment-related adverse events, while noted, appear manageable.
Read more →RVMDRevolution Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference
Revolution Medicines, Inc. has announced that its CEO, Mark A. Goldsmith, will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024. The presentation will outline the company's progress in developing targeted therapies for RAS-addicted cancers and provide updates on their R&D pipeline. Revolution Medicines focuses on creating RAS(ON) inhibitors and companion treatments, with several inhibitors currently in clinical development.
Read more →RVMDRevolution Medicines Completes Acquisition of EQRx
Revolution Medicines has successfully acquired EQRx, gaining about $1.1 billion in net cash, which will support its clinical programs for RAS-addicted cancers. The acquisition allows Revolution Medicines to issue approximately 55 million shares as part of the merger, with Dr. Sandra Horning joining its board of directors to enhance the company's leadership. EQRx's operations and stock will be wound down following the acquisition. The transaction marks a significant financial step for Revolution Medicines as it continues to develop its pipeline of oncology therapies.
Read more →RVMDRevolution Medicines and EQRx Stockholders Approve EQRx Acquisition
Revolution Medicines, Inc. and EQRx, Inc. stockholders have approved the acquisition of EQRx by Revolution Medicines. The transaction is set to close in November 2023, pending customary closing conditions. EQRx shareholders will receive Revolution Medicines stock in exchange for their shares, along with cash for any fractional shares. This merger is positioned to enhance Revolution Medicines' oncology-focused portfolio and increase its market presence.
Read more →RVMDRevolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate Progress Promising clinical data for RMC-6236, a RAS MULTI (ON) Inhibitor, and RMC-6291, a RAS G12C (ON) Inhibitor, presented at A
Revolution Medicines, Inc. announced its third quarter 2023 financial results and highlighted significant progress in its clinical programs for RMC-6236 and RMC-6291, two investigational drugs targeting RAS mutations in cancer. Positive clinical data support advancing RMC-6236 into late-stage development, and the acquisition of EQRx is anticipated to enhance financial resources. However, the company reported no revenue for the quarter and an increase in R&D expenses, which could pose challenges moving forward. A webcast will provide further insights into these developments.
Read more →RVMDLeading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Revolution Medicines Stockholders Vote FOR Proposed Acquisition of EQRx, Inc. Revolution Medicines Also Announces the Final Exchange Ratio of 0.1112
Revolution Medicines, Inc. has received favorable recommendations from leading proxy advisory firms ISS and Glass Lewis for its proposed acquisition of EQRx, Inc. Scheduled for a stockholder vote on November 8, 2023, the acquisition is expected to enhance Revolution Medicines' balance sheet by adding approximately $1.1 billion in cash. This financial boost will support the advancement of its RAS(ON) Inhibitor pipeline, which includes several critical therapies currently in clinical development. The acquisition is anticipated to close in November 2023, pending the necessary stockholder approvals.
Read more →RVMDRevolution Medicines to Report Financial Results for Third Quarter 2023 After Market Close on November 6, 2023
Revolution Medicines, Inc. (Nasdaq: RVMD) will announce its third quarter financial results on November 6, 2023, after market close. A webcast is scheduled for 4:30 p.m. ET, where the senior management team will discuss the financial outcomes and provide updates on corporate developments. The company specializes in targeted therapies for RAS-addicted cancers and is actively advancing its R&D pipeline.
Read more →RVMDRevolution Medicines Presents Promising Clinical Activity and Safety Data from Phase 1/1b Trial of RMC-6236
Revolution Medicines announced promising data from the Phase 1/1b trial of RMC-6236, an oral RASMULTI(ON) inhibitor, targeting RAS-mutated NSCLC and PDAC. Initial results show an objective response rate of 38% in NSCLC patients with a disease control rate of 85%. The treatment was generally well tolerated, though some adverse events were reported. Overall, the data support the ongoing development of RMC-6236 as a potential therapy for these hard-to-treat cancers.
Read more →RVMDRevolution Medicines Presents Encouraging Clinical Data for RMC-6236 and RMC-6291 at 2023 Triple Meeting
Revolution Medicines presented positive preliminary clinical data for its RAS inhibitors RMC-6236 and RMC-6291 during the 2023 Triple Meeting. RMC-6236 has demonstrated anti-tumor activity in various RAS mutations and a favorable safety profile, while RMC-6291 shows promising differentiation from existing treatments. The continuing developments aim to provide effective therapies for patients with RAS-addicted cancers. An investor webcast is scheduled to discuss these findings in greater detail.
Read more →RVMDRevolution Medicines to Present New Clinical Data at Major Oncology Conferences and Host Investor Webcast
Revolution Medicines, Inc. (RVMD) has announced plans to present new clinical data for its RAS(ON) inhibitors, RMC-6236 and RMC-6291, at two major oncology conferences in October 2023. At the Triple Meeting, the company will provide initial assessments of RMC-6291 and further safety profiles for RMC-6236. Additionally, at the European Society for Medical Oncology Congress, updated antitumor activity data for RMC-6236 will be shared. An investor webcast is scheduled to follow the ESMO presentation, focusing on the clinical data and the company’s overall pipeline strategy.
Read more →RVMDRevolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor
Revolution Medicines has initiated the first patient dosing in its Phase 1/1b clinical trial for RMC-9805, an oral inhibitor targeting the KRASG12D mutation. This initiation marks a significant milestone as RMC-9805 is the third oral RAS(ON) inhibitor to begin clinical evaluation by the company. The trial aims to evaluate the safety and tolerability of the drug in patients with advanced solid tumors driven by the KRASG12D mutation, which is prevalent in various cancer types. The RMC-9805 study is expected to provide insights that could inform future treatment standards for RAS-addicted cancers.
Read more →RVMDRevolution Medicines Announces Publication Describing Molecular Basis of Tri-Complex Inhibitors Targeting Oncogenic RAS(ON) Proteins
Revolution Medicines announced the publication of a research paper in Science detailing their tri-complex inhibitor approach for targeting active mutant RAS proteins, which are implicated in many cancers. The study shows that their compounds, RMC-4998 and RMC-6291, effectively inhibit oncogenic signaling in KRASG12C-dependent tumor cells, leading to significant tumor regressions in models. RMC-6291, the first mutant-selective RAS(ON) inhibitor entering clinical development, is currently being evaluated in a Phase 1/1b trial for advanced KRASG12C mutant solid tumors. This publication serves as preclinical validation of their RAS innovation platform, with more findings expected in October 2023.
Read more →RVMDRevolution Medicines Reports Second Quarter 2023 Financial Results and Update on Corporate Progress Company to provide clinical updates for RMC-6236 at Triple (AACR-NCI-EORTC) Meeting and ESMO (European Society for Medic
Revolution Medicines reported its financial results for Q2 2023 and provided updates on its pipeline advancements in RAS-targeted therapies. The company plans to present clinical data for its investigational drugs, RMC-6236 and RMC-6291, at the upcoming Triple Meeting and ESMO Congress in October. The recent acquisition of EQRx is expected to bolster the company's financial position with over $1 billion added to their capital. Additionally, plans for significant clinical trials for RMC-6236 are underway, signaling increasing confidence in their RAS-focused therapies.
Read more →RVMDRevolution Medicines to Report Financial Results for Second Quarter 2023 After Market Close on August 8, 2023
Revolution Medicines, Inc. has announced that it will release its financial results for Q2 2023 on August 8, 2023, after market close. The company specializes in developing targeted therapies for RAS-addicted cancers and plans to host a webcast at 4:30 p.m. Eastern Time to discuss these results and corporate progress. A replay of the webcast will be available on their website for at least 14 days after the event.
Read more →RVMDRevolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional Capital
Revolution Medicines, Inc. has announced its intention to acquire EQRx, Inc. in an all-stock transaction aimed at boosting its financial resources with over $1 billion in additional capital. The acquisition, approved by both companies' boards, allows Revolution Medicines to enhance its capabilities in developing targeted therapies for RAS-addicted cancers. The deal is expected to close in November 2023, subject to customary closing conditions and regulatory approvals. As part of strategic prioritization, Revolution Medicines will not continue EQRx's research and development portfolio following the acquisition.
Read more →RVMDFORM OF PARENT STOCKHOLDER VOTING AGREEMENT This Voting Agreement (this Agreement ) is made and entered into as of
EQRx, Inc. has entered into a Voting Agreement with stockholders of Revolution Medicines, Inc. as part of a merger agreement. This agreement outlines the terms under which stockholders will vote regarding the merger transactions involving Equinox Merger Sub I, Inc. and Equinox Merger Sub II LLC. The deal is designed to facilitate the merger process, ensuring stockholder cooperation and compliance with specific terms until the completion of the transaction.
Read more →RVMDRevolution Medicines to Participate in TD Cowen 4th Annual Oncology Innovation Summit
Revolution Medicines announced the participation of CEO Mark A. Goldsmith at the TD Cowen 4th Annual Oncology Innovation Summit, taking place virtually on May 30-31, 2023. Goldsmith will speak in a fireside chat scheduled for May 31 at 12:30 p.m. Eastern. This involvement underscores the company's commitment to sharing insights on their clinical developments in RAS-addicted cancers. The event will also provide a platform for engaging with a wider audience through live and replay options for the webcast.
Read more →RVMDRevolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate Progress First Wave of Investigational RAS(ON) Inhibitors – RMC-6236 (RAS MULTI ), RMC-6291 (KRAS G12C ) and RMC-9805 (KRAS
Revolution Medicines has reported its financial results for Q1 2023, highlighting a strong start for the year. The company is advancing its investigational RAS(ON) inhibitors, including progressing the Phase 1/1b study of RMC-6236, which shows potential anti-tumor activity. Additionally, it successfully raised $345 million through a public equity offering, enhancing their financial position for further development. Leadership enhancements across various departments support the clinical advancement of their drug candidates.
Read more →RVMDRevolution Medicines to Report Financial Results for First Quarter 2023 After Market Close on May 8, 2023
REDWOOD CITY, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the first quarter 2023 on Mo
Read more →RVMDRevolution Medicines to Participate in 22nd Annual Needham Healthcare Conference
REDWOOD CITY, Calif., April 13, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer
Read more →RVMDRevolution Medicines to Present Preclinical Data at the Upcoming American Association for Cancer Research Annual Meeting 2023
REDWOOD CITY, Calif., April 06, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the company and its collaborators will present preclinical data at the upc
Read more →RVMDRevolution Medicines Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
REDWOOD CITY, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the closing of its underwritten public offering of 15,681,818 shares of co
Read more →RVMDRevolution Medicines Announces Pricing of $300.0 Million Public Offering of Common Stock
REWOOD CITY, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the pricing of its underwritten public offering of 13,636,364 shares of com
Read more →RVMDRevolution Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Update on Corporate Progress Early clinical data on RMC-6236 provided in support of RAS(ON) Inhibitor platform validation Additional da
Revolution Medicines reported its financial results for 2022 and provided updates on its clinical pipeline, particularly RMC-6236 and RMC-6291. Early clinical data indicate encouraging antitumor activity for RMC-6236, and the company plans to advance several candidates, including RMC-9805 and RMC-0708, into clinical development. Future data releases are anticipated for both RMC-6236 and RMC-6291, which target different KRAS mutations linked to various cancers. Overall, the company is optimistic about the potential of its developing therapies to address RAS-driven cancers.
Read more →RVMDRevolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2022 After Market Close on February 27, 2023
REDWOOD CITY, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the fourth quarter and full
Read more →RVMDRevolution Micro and OSRAM Score in Top Ten of Global SSL Awards
Atlanta, GA, Feb. 21, 2023 (GLOBE NEWSWIRE) -- The Global SSL Awards are designed to recognize outstanding achievements in Solid State Lighting Science and Technology and is one of the highest honors in the global SSL field. The panel of judges is comprised of experts and Nobel p
Read more →RVMDOn Target to Outsmart Cancer TM
Revolution Medicines (RVMD) has unveiled its strategic focus on tackling RAS-addicted cancers through a robust pipeline of innovative drug candidates. Notably, RMC-6236, a first-in-class inhibitor, demonstrates promising anti-tumor activity in several major cancer models. The company highlights the significant clinical validation indicating the efficacy of targeting RAS mutant signaling pathways. However, the forward-looking statements caution that the development remains subject to various risks and uncertainties, particularly concerning FDA approval and ongoing clinical evaluations.
Read more →RVMDRevolution Medicines to Present at 41st Annual J.P. Morgan Healthcare Conference
REDWOOD CITY, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer
Read more →RVMDRevolution Medicines Announces Publication Describing Design and Synthesis of RMC-5552, a First-in-Class, Bi-Steric mTORC1-Selective Inhibitor
Findings Published in the Journal of Medicinal Chemistry Demonstrate Compound’s Exceptional Selectivity for mTORC1 over mTORC2 Tumor Regressions Observed During Combination Treatment with a Bi-Steric mTORC1-Selective Inhibitor and a KRASG12C-Selective Inhibitor in Preclinical Lu
Read more →RVMDRevolution Medicines to Regain Global Rights to RMC-4630 following Sanofi’s Termination of SHP2 Inhibitor Development and Commercialization Collaboration
REDWOOD CITY, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that Sanofi has provided notice of termination of the parties’ global SHP2
Read more →RVMDRevolution Medicines Reports Third Quarter 2022 Financial Results and Update on Corporate Progress Dose escalation ongoing in Phase 1/1b trials evaluating two RAS(ON) Inhibitor drug candidates, RMC-6236 (RAS MULTI inhibi
Revolution Medicines Reports Third Quarter 2022 Financial Results and Update on Corporate Progress Dose escalation ongoing in Phase 1/1b trials evaluating two RAS(ON) Inhibitor drug candidates, RMC-6236 (RASMULTI inhibitor) and RMC-6291 (KRASG12C inhibitor) Completed successfu
Read more →RVMDRevolution Medicines to Report Financial Results for Third Quarter 2022 After Market Close on November 7, 2022
REDWOOD CITY, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the third quarter 2022 on M
Read more →RVMDRevolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-6291, Company’s First Mutant-Selective RAS(ON) Inhibitor
KRASG12C(ON) Inhibitor with highly differentiated mechanism of action being evaluated in patients with cancers harboring KRASG12C mutation RMC-6291 is first mutant-selective RAS(ON) Inhibitor to enter clinic, following closely behind company’s RASMULTI(ON) Inhibitor, RMC-6236 R
Read more →RVMDRevolution Medicines Strengthens Senior Management Team with Promotions and a New Hire
Company Promotes Jack Anders to Chief Financial Officer and Jeff Cislini to General Counsel Daniel Simon to Join Company as Chief Business Officer REDWOOD CITY, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology compa
Read more →RVMDRevolution Medicines Reports Second Quarter 2022 Financial Results and Update on Corporate Progress First two RAS(ON) Inhibitor drug candidates advance into clinical development Successful equity financing supports devel
Revolution Medicines Reports Second Quarter 2022 Financial Results and Update on Corporate Progress First two RAS(ON) Inhibitor drug candidates advance into clinical development Successful equity financing supports development of portfolio of targeted drug candidates for RAS-a
Read more →RVMDRevolution Medicines to Report Financial Results for Second Quarter 2022 After Market Close on August 9, 2022
REDWOOD CITY, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the second quarter 2022 on
Read more →RVMDRevolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
REDWOOD CITY, Calif., July 22, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the closing of an underwritten public offering of 13,225,000 shares of comm
Read more →RVMDRevolution Medicines Announces Pricing of Upsized $230.0 Million Public Offering of Common Stock
REDWOOD CITY, Calif., July 19, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the pricing of its underwritten public offering of 11,500,000 shares of com
Read more →RVMDRevolution Medicines Appoints Lorence Kim, M.D., Accomplished Health Care Industry Leader, to Board of Directors
REDWOOD CITY, Calif., July 13, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the appointment of Lorence Kim, M.D., to its board of directors. Dr. Kim ha
Read more →RVMDRevolution Medicines Advances First RAS(ON) Inhibitor into Clinic, Dosing First Patient in Phase 1/1b Trial of RMC-6236
First-in-class, oral, RAS(ON) Inhibitor being evaluated initially in patients with cancers driven by KRASG12 mutations Sushil Patel, Ph.D., industry veteran with commercial oncology expertise, elected to board of directors REDWOOD CITY, Calif., June 28, 2022 (GLOBE NEWSWIRE) --
Read more →RVMDRevolution Medicines to Participate in the 43rd Annual Goldman Sachs Global Healthcare Conference
REDWOOD CITY, Calif., June 09, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that the company will participate in the 43rd Annual Goldman Sachs Global H
Read more →RVMDRevolution Medicines Reports First Quarter 2022 Financial Results and Update on Corporate Progress Lead RAS(ON) Inhibitor drug candidates RMC-6236 (RAS MULTI ) and RMC-6291 (KRAS G12C ) approaching the clinic RMC-4630-03
Revolution Medicines Reports First Quarter 2022 Financial Results and Update on Corporate Progress Lead RAS(ON) Inhibitor drug candidates RMC-6236 (RASMULTI) and RMC-6291 (KRASG12C) approaching the clinic RMC-4630-03 Phase 2 trial evaluating RAS Companion Inhibitor RMC-4630
Read more →RVMDRevolution Medicines to Report Financial Results for First Quarter 2022 After Market Close on May 9, 2022
REDWOOD CITY, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the first quarter 2022 on
Read more →RVMDRevolution Medicines Announces Seven Oral Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2022
REDWOOD CITY, Calif., March 09, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the company will make seven oral presentations at the upcoming American As
Read more →RVMDRevolution Medicines to Participate in Cowen 42nd Annual Health Care Conference
REDWOOD CITY, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that the company will participate in the Cowen 42nd Annual Health Ca
Read more →RVMDRevolution Medicines Reports Fourth Quarter and Year-End 2021 Financial Results and Update on Corporate Progress RAS(ON) Inhibitor Pipeline Continues to Advance and Expand, Now Addressing Majority of RAS-Addicted Cancers
Revolution Medicines Reports Fourth Quarter and Year-End 2021 Financial Results and Update on Corporate Progress RAS(ON) Inhibitor Pipeline Continues to Advance and Expand, Now Addressing Majority of RAS-Addicted Cancers; Two New Drug Candidates Recently Nominated Announced F
Read more →RVMDRevolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2021 After Market Close on February 28, 2022
REDWOOD CITY, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the fourth quarter and full
Read more →RVMDRevolution Medicines to Participate in Guggenheim Healthcare Talks 2022 Oncology Conference
REDWOOD CITY, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that the company will participate in the Guggenheim Healthcare Talks
Read more →RVMDOn Target to Outsmart CancerTM Legal Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act. All statements other than statements of historical
On Target to Outsmart CancerTM Legal Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act. All statements other than statements of historical facts contained in this presentation, including statement
Read more →RVMDRevolution Medicines Reports Progress Across Pipeline of Targeted Therapeutics for RAS-Addicted Cancers in Presentation at 40th Annual J.P. Morgan Healthcare Conference
RAS(ON) Inhibitor Pipeline Expands with Advancement of Two New Drug Candidates; Development-Stage Portfolio Covers RAS Drivers of Majority of RAS-Addicted Cancers First Patient Dosed in Global Phase 2 Clinical Trial Evaluating Combination of RMC-4630 and Lumakras™ (sotorasib) in
Read more →RVMDRevolution Medicines to Provide R&D Update, Including Expansion of Development-Stage RAS(ON) Inhibitor Pipeline, During Presentation at 40th Annual J.P. Morgan Healthcare Conference
REDWOOD CITY, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies for RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executi
Read more →RVMDRevolution Medicines to Participate in 4th Annual Evercore ISI HealthCONx Conference
REDWOOD CITY, Calif., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, today announced that the co
Read more →RVMDRevolution Medicines Reports Third Quarter Financial Results and Update on Corporate Progress RAS(ON) Inhibitor Development Candidates Targeting KRAS G12C and RAS MULTI Progressing Toward the Clinic; Company Showed Addit
Revolution Medicines Reports Third Quarter Financial Results and Update on Corporate Progress RAS(ON) Inhibitor Development Candidates Targeting KRASG12C and RASMULTI Progressing Toward the Clinic; Company Showed Additional Preclinical Data Supporting Benefits and Differentiatio
Read more →RVMDRevolution Medicines to Participate in Stifel 2021 Virtual Healthcare Conference
REDWOOD CITY, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, today announced that the co
Read more →RVMDRevolution Medicines to Report Financial Results for Third Quarter 2021 After Market Close on November 10, 2021
REDWOOD CITY, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, today announced that it wil
Read more →RVMDRevolution Medicines to Present New Preclinical Data from RAS(ON) Inhibitor Programs at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
REDWOOD CITY, Calif., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, today announced that new p
Read more →RVMDRevolution Medicines to Participate in 3rd Annual RAS-Targeted Drug Development Summit
REDWOOD CITY, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, today announced that the c
Read more →RVMDRevolution Medicines to Present at H.C. Wainwright 23rd Annual Global Investment Conference
REDWOOD CITY, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, today announced that Mark
Read more →RVMDRevolution Medicines Reports Second Quarter Financial Results and Update on Corporate Progress Company Shows Continued Progress Demonstrating Differentiation of RAS(ON) Inhibitors, Targeting Additional RAS Variants and P
Revolution Medicines Reports Second Quarter Financial Results and Update on Corporate Progress Company Shows Continued Progress Demonstrating Differentiation of RAS(ON) Inhibitors, Targeting Additional RAS Variants and Progressing Assets Toward the Clinic RMC-4630-02 Study Sup
Read more →RVMDRevolution Medicines to Report Financial Results for Second Quarter 2021 After Market Close on August 11, 2021
REDWOOD CITY, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, today announced that it wil
Read more →RVMDRevolution Medicines Announces Publication of Scientific Paper Describing Novel Class of Anti-Tumor Compounds Targeting mTORC1
REDWOOD CITY, Calif., June 24, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced the publication of an origi
Read more →RVMDRevolution Medicines to Host Science Talk Webcast Highlighting Learnings from Recent Preclinical and Clinical Studies of RAS Inhibitors
REDWOOD CITY, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced that it will host a Science Talk webca
Read more →RVMDRevolution Medicines to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference
REDWOOD CITY, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced that the company will participate in t
Read more →RVMDRevolution Medicines to Participate in Cowen 2nd Annual Virtual Oncology Innovation Summit
REDWOOD CITY, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced that the company will participate in th
Read more →RVMDRevolution Medicines Reports First Quarter Financial Results and Update on Corporate Progress Multiple AACR Presentations Highlight Potential Advantages of RAS(ON) Inhibitors; Scientific Publication is First to Demonstra
Revolution Medicines Reports First Quarter Financial Results and Update on Corporate Progress Multiple AACR Presentations Highlight Potential Advantages of RAS(ON) Inhibitors; Scientific Publication is First to Demonstrate Anti-Drug Resistance Features Continued Advancement an
Read more →RVMDRevolution Medicines Highlights Slate of Diverse Board of Directors Nominees for Upcoming 2021 Annual Shareholder Meeting
REDWOOD CITY, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today highlights the nomination of a slate o
Read more →RVMDRevolution Medicines Announces Dosing of First Patient in Phase 1/1b Clinical Study of RMC-5552 in Patients with Advanced Solid Tumors
First-in-Class Bi-steric mTORC1 Inhibitor Advances into Clinical Development Newly Issued U.S. Patent Further Strengthens RMC-5552 IP Portfolio REDWOOD CITY, Calif., April 21, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncolog
Read more →RVMDRevolution Medicines Announces Six Presentations at the American Association for Cancer Research Annual Meeting 2021
REDWOOD CITY, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced the company will make six
Read more →RVMDRevolution Medicines Reports Fourth Quarter and Year-End 2020 Financial Results and Update on Corporate Progress Advanced and Expanded Portfolio of RAS(ON) Inhibitors; Two Assets Entered IND-Enabling Development Continue
Revolution Medicines Reports Fourth Quarter and Year-End 2020 Financial Results and Update on Corporate Progress Advanced and Expanded Portfolio of RAS(ON) Inhibitors; Two Assets Entered IND-Enabling Development Continued Progress in Development of RAS Companion Inhibitors to
Read more →RVMDRevolution Medicines to Participate in Digital RAS-Targeted Drug Discovery Summit and Upcoming Investor Conferences
REDWOOD CITY, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced that the company will participate in t
Read more →RVMDRevolution Medicines Announces Pricing of Upsized $260.9 Million Public Offering of Common Stock
REDWOOD CITY, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD) today announced the pricing of its underwritten public offering of 5,797,101 shares of common stock at a public offering price of $45.00 per share, before underwriting discounts and
Read more →RVMDRevolution Medicines Announces Proposed Public Offering of Common Stock
REDWOOD CITY, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD) today announced that it has commenced an underwritten public offering of 4,000,000 shares of common stock. All of the shares of common stock are being offered by Revolution Medicines
Read more →RVMDRevolution Medicines to Provide R&D Pipeline Update, Including Progress of RAS(ON) Inhibitor Programs, During Presentation at 39th Annual J.P. Morgan Healthcare Conference
REDWOOD CITY, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., c
Read more →RVMDRevolution Medicines Reports Third Quarter 2020 Financial Results and Update on Corporate Progress Recommended Phase 2 Dose and Schedule Selected for Further Evaluation of RMC-4630 as Monotherapy and RMC-4630 plus Cobime
Revolution Medicines Reports Third Quarter 2020 Financial Results and Update on Corporate Progress Recommended Phase 2 Dose and Schedule Selected for Further Evaluation of RMC-4630 as Monotherapy and RMC-4630 plus Cobimetinib Combination First-in-Class RAS(ON) Inhibitor Progr
Read more →RVMDRevolution Medicines Reports Progress and Expansion of Combination Strategy with RMC-4630 as Therapeutic Backbone for RAS-Addicted Cancers
Plenary Presentation at EORTC-NCI-AACR 32nd Symposium on Molecular Targets and Cancer Therapeutics Describes Encouraging Tolerability and Exposure Profiles for RMC-4630 Combined with Cobimetinib and Early Evidence of Clinical Activity in RASmut Colorectal Cancers Company Also An
Read more →RVMDRevolution Medicines to Present Interim Data at ENA 2020 from Phase 1b/2 Clinical Trial Combining RMC-4630 with Cobimetinib for RAS-Addicted Solid Tumors
REDWOOD CITY, Calif., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced that interim data from the company’s o
Read more →RVMDRevolution Medicines Reports Preclinical Tumor Regressions Induced by First-in-Class KRAS-G12D(ON) Inhibitors
Presentation at 2nd Annual RAS-Targeted Drug Development Conference Highlights First Publicly Reported Data for Inhibitors of Notorious Cancer Protein KRASG12D(ON) REDWOOD CITY, Calif., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stag
Read more →RVMDRevolution Medicines to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
REDWOOD CITY, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced that Mark A. Goldsmith, M.
Read more →RVMDRevolution Medicines to Participate in 2nd Annual RAS-Targeted Drug Development Conference
REDWOOD CITY, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced that the company will part
Read more →RVMDRevolution Medicines Reports Second Quarter 2020 Financial Results and Provides Update on Corporate Progress Interim RMC-4630 Data Support Benefit of Intermittent Dosing and Corroborate Clinical Activity Against Genetica
Revolution Medicines Reports Second Quarter 2020 Financial Results and Provides Update on Corporate Interim RMC-4630 Data Support Benefit of Intermittent Dosing and Corroborate Activity Against Genetically-Defined Tumors Targeted Combination Strategy Underpins Initiation of Ne
Read more →RVMDRevolution Medicines Announces Pricing of $156.0 Million Public Offering of Common Stock
REDWOOD CITY, Calif., July 08, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD) today announced the pricing of its underwritten public offering of 6,000,000 shares of common stock at a public offering price of $26.00 per share, before underwriting discounts and c
Read more →RVMDRevolution Medicines Reports New Application of Tri-Complex Modality for “Undruggable” Protein Targets and Announces License to Ginkgo Bioworks to Explore Potential Use Against Novel Coronavirus
REDWOOD CITY, Calif. and BOSTON, June 30, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier cancer targets, today announced the publication of an original scientific p
Read more →RVMDRevolution Medicines Announces Dosing of First Patient in Clinical Study of RMC-4630 (SAR442720) Combined with PD-1 Inhibitor
REDWOOD CITY, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier cancer targets, today announced dosing of the first patient in a multicenter Phase 1 c
Read more →RVMDRevolution Medicines Provides Research and Development Update for its Portfolio of Novel Targeted Cancer Therapies
REDWOOD CITY, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier cancer targets, today provided a research and development (R&D) update regarding the c
Read more →RVMDLegal Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act. All statements other than statements of historical facts contained in this presen
June 2020 Translating Frontier Oncology Targets to Outsmart Cancer Exhibit 99.1 Legal Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act. All statements other than statements of historical facts c
Read more →RVMDRevolution Medicines Appoints Eric T. Schmidt, Ph.D. and Peter Svennilson to its Board of Directors
REDWOOD CITY, Calif., June 18, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier cancer targets, today announced the appointments of Eric T. Schmidt, Ph.D., and Peter
Read more →RVMDRevolution Medicines Announces Dosing of First Patient in Phase 1b Combination Study of RMC-4630 and AMG 510
Study Evaluates Combination Treatment with Investigational SHP2 and KRASG12C Inhibitors in Patients with KRASG12C Mutant Solid Tumors REDWOOD CITY, Calif., June 09, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on d
Read more →RVMDRevolution Medicines Announces Four Presentations at the 2020 American Association for Cancer Research Virtual Annual Meeting II
REDWOOD CITY, Calif., May 19, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier cancer targets, today announced the company will make four presentations at the upcomin
Read more →RVMDRevolution Medicines Reports First Quarter 2020 Financial Results and Continued Corporate Progress Closed Initial Public Offering Raising Gross Proceeds of $273.7 Million Presented First Evidence of Clinical Activity of
Revolution Medicines Reports First Quarter 2020 Financial Results and Continued Corporate Progress Closed Initial Public Offering Raising Gross Proceeds of $273.7 Million Presented First Evidence of Clinical Activity of SHP2 Inhibitor (RMC-4630) Against KRAS Mutant Lung Precli
Read more →RVMDRevolution Medicines Announces Publication of Scientific Paper Describing Anti-Tumor Immunity Induced by SHP2 Inhibitor in Preclinical Cancer Models
REDWOOD CITY, Calif., April 29, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier cancer targets, today announced the publication of an original scientific paper in Ca
Read more →RVMDRevolution Medicines Announces Issuance of U.S. Patent Covering Compositions of Matter for its Clinical-Stage SHP2 Inhibitor Program
REDWOOD CITY, Calif., March 18, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier cancer targets, today announced that the United States Patent and Trademark Office ha
Read more →RVMDRevolution Medicines Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
REDWOOD CITY, Calif., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit elusive frontier targets within notorious cancer pathways, today announced the closing of its i
Read more →RVMDRevolution Medicines Announces Pricing of Initial Public Offering
REDWOOD CITY, Calif., Feb. 12, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD) today announced the pricing of its initial public offering of 14,000,000 shares of common stock at a public offering price of $17.00 per share, before underwriting discounts and commi
Read more →RVMDRevolutionary Changes Ahead with Innovative 5G Uses
5G to re-shape smart cities, cloud gaming, smart energy grids and many other industries 1.3 billion 5G connections predicted by 2023 Up to $13.2 trillion in sales enablement and support 22.3 million jobs by 2035 BELLEVUE, Wash., Nov. 18, 2019 (GLOBE NEWSWIRE) -- With 46 5G net
Read more →RVMDRevolutions Medical's Proprietary MRI Software Tools Being Utilized in Additional IRB Approved Clinical Study
CHARLESTON, S.C., Jan. 19, 2011 (GLOBE NEWSWIRE) -- Revolutions Medical ("Revolutions Medical" or the "Company") (OTCBB:RMCP) has received notice that Investigational Review Board (IRB) approval has been granted to Dr. Yong Wei, Assistant Professor of Computer Science at North Ge
Read more →RVMDRevolutions Medical Discusses Presentation of MRI Paper at IPCV and Relevance to Clinical Application Studies
CHARLESTON, S.C., Aug. 20, 2010 (GLOBE NEWSWIRE) -- Revolutions Medical Corporation ("Revolutions Medical" or the "Company") (OTCBB:RMCP) announces additional details regarding clinical studies and presentation of related MRI paper at IPCV (Image Processing and Computer Vision) b
Read more →RVMDRevolutions Medical Corporation Begins Clinical Applications and Validation Process of Its MRI Software Tools
CHARLESTON, S.C., Aug. 16, 2010 (GLOBE NEWSWIRE) -- Revolutions Medical Corporation ("Revolutions Medical" or the "Company") (OTCBB:RMCP), begins collaboration with H. Keith Brown, PhD, Philadelphia College of Osteopathic Medicine, on two clinical applications using their proprie
Read more →Competitive Position
How RVMD ranks across every disease it competes inCompetitive Position is a premium feature
See how RVMD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial